中国HIV-1 B'/C亚型感染者对异体病毒中和作用与疾病进展关系研究
중국HIV-1 B'/C아형감염자대이체병독중화작용여질병진전관계연구
Study on the relationships between neutralizing antibody response against heterologous virus and disease progression of HIV type 1 B'/C infected individuals in China
  • 万方数据
    中华微生物学和免疫学杂志 중화미생물학화면역학잡지
    CHINESE JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY
    2009年 2期 165-169 ,共5页

    包名家%耿文清%崔华露%张晓丽%徐东兵%王亚婷%潘莹%姜拥军%王亚男%韩晓旭%张旻%张子宁%尚红

    포명가%경문청%최화로%장효려%서동병%왕아정%반형%강옹군%왕아남%한효욱%장민%장자저%상홍

    HIV-1%B'/C亚型%中和抗体%异体病毒 HIV-1%B'/C亞型%中和抗體%異體病毒
    HIV-1%B'/C아형%중화항체%이체병독
    HIV-1%B'/C subtype%Neutralizing antibodies%Heterologous virus
    目的 探讨中国HIV-1 B'/C亚型感染者对异体病毒中和作用与疾病进展的关系.方法 根据CD4 T淋巴细胞数量和有尤临床症状将HIV-1 B'/C亚型感染者分为HIV慢性感染组和AIDS组.将HIV-1感染者血清稀释(1/10～1/320)后,与在基因结构特点上同源性很低的3株HIV-1作用,以检测其中和作用.同时以正常人血清加病毒悬液为对照孔,能够抑制对照孔50%病毒复制的血清为中和作用阳性.将某个HIV-1感染者血浆能够中和异体病毒的个数占3个异体病毒的百分率定义为HIV-1感染者中和异体病毒的宽度;将某个HIV-1感染者血浆中和3个异体病毒抗体滴度的几何平均滴度定义为HIV-1感染者中和异体病毒的强度.结果 HIV-1慢性感染组与AIDS组之间中和异体病毒的宽度和强度差异有统计学意义,HIV-1慢性感染组显著高于AIDS组.HIV-1慢性感染组中和异体病毒的宽度和强度与病毒载量呈正相关,而AIDS组巾和异体病毒的宽度和强度与病毒载量没有显著的相关性.HIV-1慢性感染组和AIDS组中和异体病毒的宽度和强度与CD4 T淋巴细胞数均没有显著的相关性.结论 中国HIV-1B'/C亚型感染者不同疾病进展阶段针对异体病毒中和作用能力不同,HIV慢性感染组显著高于AIDS组,当疾病进展到AIDS期时,失去对异体病毒的中和作用,提示针对异体病毒的中和抗体与疾病进程有关.
    목적 탐토중국HIV-1 B'/C아형감염자대이체병독중화작용여질병진전적관계.방법 근거CD4 T림파세포수량화유우림상증상장HIV-1 B'/C아형감염자분위HIV만성감염조화AIDS조.장HIV-1감염자혈청희석(1/10～1/320)후,여재기인결구특점상동원성흔저적3주HIV-1작용,이검측기중화작용.동시이정상인혈청가병독현액위대조공,능구억제대조공50%병독복제적혈청위중화작용양성.장모개HIV-1감염자혈장능구중화이체병독적개수점3개이체병독적백분솔정의위HIV-1감염자중화이체병독적관도;장모개HIV-1감염자혈장중화3개이체병독항체적도적궤하평균적도정의위HIV-1감염자중화이체병독적강도.결과 HIV-1만성감염조여AIDS조지간중화이체병독적관도화강도차이유통계학의의,HIV-1만성감염조현저고우AIDS조.HIV-1만성감염조중화이체병독적관도화강도여병독재량정정상관,이AIDS조건화이체병독적관도화강도여병독재량몰유현저적상관성.HIV-1만성감염조화AIDS조중화이체병독적관도화강도여CD4 T림파세포수균몰유현저적상관성.결론 중국HIV-1B'/C아형감염자불동질병진전계단침대이체병독중화작용능력불동,HIV만성감염조현저고우AIDS조,당질병진전도AIDS기시,실거대이체병독적중화작용,제시침대이체병독적중화항체여질병진정유관.
    Objective To study the relationships between neutralizing antibody response against heterologous virus and disease progression in Chinese HIV-1 B'/C infected individuals. Methods Plasmas from HIV-1-infected individuals, grouped as HIV chronically infected or AIDS according to CD4+ count and clinical symptom, were tested for neutralizing activity against the three HIV-1 isolates with very low homology in vitro. Six two-fold dilutions of each plasma sample (from 1/10 to 1/320) were tested against each virus from the panel. Giving a 50% reduction in p24Ag compared with normal human plasma control wells was defined as positive. The breadth of the cross-neutralizing response was defined based on the number of viruses that were effectively neutralized by any given patient-derived plasma sample. The magnitude of the crossneutralizing response was defined based on the average neutralizing titer against all heterologous viruses. Resuits We found that there revealed a significant difference between HIV chronically infected and AIDS group in the breaths and magnitudes of neutralizing heterologous virus. There was higher prevalence for the frequency of neutralizing heterologous virus in HIV chronically infected than AIDS. The results showed that there was positive correlation between the breadths and magnitudes of neutralizing response against heterologous virus and the plasma HIV RNA level in HIV chronically infected group, while not in AIDS group. There was no association between the breadth of the neutralizing responses against heterologous virus and CD4 T cell counts. Conclusion The capacity of neutralizing antibodies against heterologous virus varied among different disease stage. There were higher titers of neutralizing antibodies in HIV chronically infected than AIDS group. The loss of neutralizing antibodies in plasma from AIDS group appears to be associated with a narrowing of the antibody response during disease progression. These suggest that the presence of neutralizing antibodies against hetreologous virus was associated with disease progression.
    원문보기 원문다운로드 사이트로이동
저자의 최근 논문